British drugmaker AstraZeneca said on Saturday its vaccine developed with Oxford University appeared to offer only limited protection against mild disease caused by the South African variant of COVID-19, based on early data from a trial.
The study from South Africa's University of the Witwatersrand and Oxford University showed the vaccine had significantly reduced efficacy against the South African variant, according to a Financial Times report published earlier in the day.
Among coronavirus variants currently most concerning for scientists and public health experts are the so-called British, South African and Brazilian variants, which appear to spread more swiftly than others.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.